Phase 3 N=1,094 Natalizumab Re-Initiation of Dosing
Multiple Sclerosis, Relapsing-Remitting
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious AEs (SAEs) — 826; 487; 66; 161 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=25 Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects
Infection
Primary: Change in Mean Number of Skin Bacterial Counts From Baseline to 72 Hours — -1.91; -1.87 log 10 CFU/cm sq — p=<0.001
Phase 3 N=660 Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
Autistic Disorder · Behavioral Symptoms
Primary: Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome…
Phase 3 N=680 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
Bipolar Disorder
Primary: Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS) — -10.19; -10.95; -9.47 scores on scale — p=0.1077
Phase 3 N=313 Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) — 139; 141…
Phase 3 N=233 A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)
Controlled Ovarian Stimulation
Primary: The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day…
Phase 3 N=3,991 Tiotropium / Respimat One Year Study in COPD.
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337 — 0.119; 0.018 Litres — p=<0.0001
Phase 3 N=78 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
Small Cell Lung Carcinoma
Primary: Overall Survival (OS) for the Full Analysis Population (FAP) — 10.2177; 9.6591 months — p=0.0556
Phase 3 N=196 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy
Narcolepsy
Primary: Change From Baseline in Maintenance of Wakefullness Test (MWT) Score at 12 Weeks — 2.6; 1.3; -1.9; 1.9 Minutes — p=0.0024
Phase 3 N=18,644 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Infections, Papillomavirus
Primary: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA…
Phase 3 N=784 Safety Study of XP12B in Women With Menorrhagia
Menorrhagia · Heavy Menstrual Bleeding
Primary: Number of Subjects With at Least One Adverse Event During the Study — 678 participants
Phase 3 N=139 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
Attention Deficit Hyperactivity Disorder · Oppositional Defiant Disorder
Primary: Change From Baseline to 8 Week Endpoint in Swanson, Nolan and Pelham Questionnaire (SNAP-IV): Attention-Deficit/Hyperactivity Disorder (ADHD) Subscale — 42.7; 41.5…
Phase 3 N=381 An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
Early Stage Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 369 Subjects
Phase 3 N=976 Open Label Study Telmisartan and Amlodipine in Hypertension
Hypertension
Primary: Trough Seated Diastolic Blood Pressure (DBP) Control — 504; 160; 19; 84 Participants
Phase 3 N=178 Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors
Hypercholesterolemia · Dyslipidemia · Coronary Heart Disease
Primary: Number of Patients Attaining NCEP LDL-C Target at Week 16 — 98; 45 particpants